NeuroOne reports successful large-animal procedures using next-generation StereoCED platform - NMTC News | RalliesNeuroOne reports successful large-animal procedures using next-generation StereoCED platform
N
NMTC• Large-animal procedures and device timeline
- NeuroOne completed three large-animal procedures using its next-generation StereoCED platform for robotic-assisted intracerebral drug delivery.
- Two procedures achieved targeted drug delivery with simultaneous intracranial electrophysiological recording from the same brain regions.
- Work supports a planned launch for human investigational clinical studies later this quarter.
- StereoCED devices for animal use finished early, enabling earlier sales; related revenue is expected to be recognized in fiscal Q4 2026.
- Devices for human investigational use remain on track for release by the end of fiscal Q4 2026.
